<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448305</url>
  </required_header>
  <id_info>
    <org_study_id>CT 4002</org_study_id>
    <secondary_id>EudraCT-Nr. 2006-002221-23</secondary_id>
    <nct_id>NCT00448305</nct_id>
  </id_info>
  <brief_title>EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients</brief_title>
  <official_title>An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and tolerability of a therapy
      with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for
      patients with relapsed or metastatic triple receptor negative breast cancer (a special
      subgroup of breast cancer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is still a major public health problem worldwide, as it is by far the most
      frequent neoplasm in women. In recent years so-called &quot;profiling of breast cancer&quot; with
      expression arrays has become common and it was suggested that the results will allow
      individualization of care. Breast cancer may now be subclassified into luminal, basal, and
      HER-2 subtypes with distinct differences in prognosis and response to therapy. About 80% of
      all basal-like-breast cancers possess a so-called &quot;triple-receptor-negative&quot; phenotype.

      Patients with &quot;triple receptor negative breast cancer&quot; have a complete absence of hormone
      receptors incl. HER-2, an aggressive clinical course and a paucity of treatment options. The
      only therapeutic option is chemotherapy and in this respect the choice of cytostatic agents
      is limited. Against this background, the study tries to find another therapeutic option by
      combining a vascular-disrupting activity with the cytostatic effects of paclitaxel in the
      study drug EndoTAG-1.

      Comparison: EndoTAG-1 + paclitaxel (combination therapy) and EndoTAG-1 (monotherapy) in
      comparison to paclitaxel (control group)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-month progression free survival (PFS) rate</measure>
    <time_frame>4 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>median progression free survival (PFS) time</measure>
    <time_frame>progression of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor response</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-month survival rate</measure>
    <time_frame>4-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median overall survival time</measure>
    <time_frame>Withdrawal or death of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain assessment</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit assessment via quality of life (QoL)Scale</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory values</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose variations</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoTAG-1 + Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoTAG-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1 + paclitaxel</intervention_name>
    <description>EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1</intervention_name>
    <description>EndoTAG-1 44 mg/m² twice weekly</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 90 mg/m² weekly</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven triple-receptor-negative metastatic or relapsed breast cancer

          -  Minimum interval of 6 months after the end of any previous taxane- containing
             chemotherapy regimen

          -  At least one tumor lesion measurable according to RECIST criteria

          -  Gender: female

          -  Age &gt;= 18 years old

          -  Negative pregnancy test (females of childbearing potential)

          -  Willingness to perform double-barrier-contraception during study and for 6 months post
             chemotherapy treatment

          -  ECOG performance status 0, 1 or 2

          -  Signed informed consent

        Exclusion Criteria:

          -  More than 1 previous chemotherapeutic treatment for metastatic or relapsed disease

          -  Major surgery &lt; 4 weeks prior to enrollment

          -  Immunotherapy &lt; 2 weeks prior to enrollment

          -  Severe pulmonary obstructive or restrictive disease

          -  Uncontrolled inflammatory disease (autoimmune or infectious)

          -  Clinically significant cardiac disease (NYHA stadium &gt; 2)

          -  Laboratory tests (hematology, chemistry) outside specified limits

          -  Pregnancy or nursing status

          -  Known positive HIV testing

          -  Known hypersensitivity to any component of the EndoTAG-1 or taxane formulations

          -  History of malignancy other than breast cancer &lt; 5 years prior to enrollment, except
             skin cancer (i.e. basal or squamous cell carcinoma) treated locally

          -  Known progressive cerebral metastasis (patients with cerebral metastases in a stable
             state or after successful surgical or radiological treatment are allowed to
             participate in the study)

          -  History of active or significant neurological disorder or psychiatric disorder that
             would prohibit the understanding and giving of informed consent, or would interfere in
             the clinical and radiological evaluation of central nervous system during the trial

          -  Concurrent treatment with other experimental drugs. Participation in another clinical
             trial with any investigational not marketed drug within 30 days prior to study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Awada, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000 Brussels, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cente Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jour Centre Henri Kaplan</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vedanta Institute of Medical Science</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Searoc Cancer Center</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeshore Hospital</name>
      <address>
        <city>Kochin</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaushalya Medical Foundation</name>
      <address>
        <city>Thane</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Centrum Onkologii</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. M. Sklodowskiej-Curie</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut im. M. Sklodowskiej-Curie</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Grupowa Specjalistyczna</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii Adadmii Medycznej</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology &quot;Prof. Dr. Al. Trestioreanu&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology &quot;Prof. Dr. I. Chiricuta&quot;</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Medical Oncology</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Hospital Sibiu</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Clinic &quot;Oncomed&quot;</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnepropetrovsk State Medical Acedamy</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Radiology of Acedamy of Medical Sciences</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Abdominal Surgery</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut of Oncology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Department</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivne Regional Oncological Dispensary</name>
      <address>
        <city>Rovno</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumy Reginal Oncology Center</name>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Uzhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>India</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2007</study_first_posted>
  <last_update_submitted>January 3, 2012</last_update_submitted>
  <last_update_submitted_qc>January 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>relapsed</keyword>
  <keyword>triple-receptor negative</keyword>
  <keyword>EndoTAG-1</keyword>
  <keyword>metastatic or relapsed breast neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

